Drugs / PT003
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03075267 | Apr → Sep 2017 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00893971 | May → Jul 2009 | — | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01587079 | Apr → Sep 2012 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01085045 | Mar → Nov 2010 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PT003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00893971 ↗ |
| Known as | GFF MDI | “PT003 (GFF MDI) 14.4/9.6 µg” NCT03075267 ↗ |
| Route | Inhaled | “Inhaled PT003, single dose” NCT00893971 ↗ |